Low-frequency cd8+T cell precursors specific for survivin and survivin-2b in cancer patients: A caveat for immunotherapy?
| dc.creator | Karanikas, V. | en |
| dc.creator | Soukou, F. | en |
| dc.creator | Kalala, F. | en |
| dc.creator | Kerenidi, T. | en |
| dc.creator | Gourgoulianis, K. | en |
| dc.creator | Germenis, A. | en |
| dc.date.accessioned | 2015-11-23T10:33:20Z | |
| dc.date.available | 2015-11-23T10:33:20Z | |
| dc.date.issued | 2008 | |
| dc.identifier.issn | 1570-5870 | |
| dc.identifier.uri | http://hdl.handle.net/11615/29049 | |
| dc.source | Cellular Oncology | en |
| dc.source.uri | <Go to ISI>://WOS:000254301100082 | |
| dc.subject | Oncology | en |
| dc.subject | Cell Biology | en |
| dc.subject | Pathology | en |
| dc.title | Low-frequency cd8+T cell precursors specific for survivin and survivin-2b in cancer patients: A caveat for immunotherapy? | en |
| dc.type | journalArticle | en |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||